Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8

BJU International

Volumn 92, Issue 6, 2003, Pages 539-544

  Manoharan, M ^a   Bird, V G ^a   Kim, S S ^a   Civantos, F ^a   Soloway, M S ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Department of Urology ^*  (United States)

Author keywords

Gleason score; Prostatectomy; Prostatic neoplasms; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; EVALUATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142092336     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04419.x     Document Type: Article

References (38)

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995; 45: 8-30
2. Adolfsson J, Sreineck G, Whitmore WF. Recent results of management of palpable clinically localized cancer. Cancer 1993; 72: 310-5
3. Zincke H, Bergstralh EJ, Blute ML et al. Radical prostatectomy for clinically localized prostate cancer, long term results of 1,143 patients from a single institution. J Clin Oncol 1994; 12: 2254-63
4. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. JAMA 1993; 269: 2633-6
5. Grossfeld GD, Latini DM, Lubeck DP et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology 2002; 59: 560
6. D'Amico AV, Whittington R, Malkowicz SB et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185
7. Paulson DF, Piserchia PV, Gardner W. Predictors of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. J Urol 1980; 123: 697
8. Sogani PC, Israel A, Lieberman PH et al. Gleason grading of prostate cancer: a predictor of survival. Urology 1985; 25: 223
9. Perrotti M, Rabbani F, Russo P, Solomon MC, Fair W. R. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors. Urology 1998; 52: 106
10. Lau WK, Bergstralh FJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer. influence of concomitant pathological variables. J Urol 2002; 167: 117
11. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507
12. Partin AW, Yoo J, Carter JB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110
13. D'Amico AV, Whittington R, Malkowicz SB et al. Pretreatment nomogram for prostate-specific antigen recurrence after prostatectomy or external-beam radiation therapy for clinically localized cancer. J Clin Onc 1999; 17: 168-72
14. Oefelein MG, Grayhack JT, McVary KT. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate. Cancer, 1995; 76: 2535-42
15. Gleason DF. Classification of prostate carcinomas. Cancer Chemother Report 1966; 50: 125
16. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837
17. Zincke H, Oesterling JE, Blute ML et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850
18. Walsh PC, Partin AW, Epstein J. I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831
19. Grossfeld GD, Chang JJ, Broering JM et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001; 165: 851-6
20. Walsh PC. Anatomical radical prostatectomy. Evolution of the surgical technique. J Urol 1998; 160: 2418
21. Soloway MS, Neulander E. Bladder-neck preservation during radical retropubic prostatectomy. Semin Urol Oncol 2000; 18: 51-6
22. True LD. Surgical pathology examination of the prostate gland: practice survey by American Society of Clinical Pathologists. Am J Clin Pathol 1994; 102: 572
23. American Joint Committee on Cancer. Beahrs OH, Henson DE, Hutter RVP eds. Manual for Staging Cancer, 4th edn. Philadelphia: JB Lippincott, 1992
24. Carvalhal GF, Humphrey PA, Thorson P et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000; 89: 1308-14
25. Amling CL, Bergstralh EJ, Blute ML et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51
26. Grossfeld GD, Latini DM, Lubeck DP. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003; 169: 157-63
27. Mian BM, Troncoso P, Okihara K et al. Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002; 167: 1675
28. Tefilli MV, Gheiler EL, Tiguert R et al. Role of radical prostatectomy in patients with prostate cancer of high Gleason score. The Prostate 1999; 39: 1
29. Pan C-C, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Path 2000; 24: 563-9
30. Ohori M, Goad JR, Wheeler TM et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-9
31. Partin AW, Lee BR, Carmichael M et al. Radical prostatectomy for high grade disease: a reevaluation in 1994. J Urol 1994; 151: 1583-6
32. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112-6
33. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 713-25
34. Zagars GK. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am 1993; 20: 737-47
35. Carroll PR, Lee KL, Fuks ZY et al. Cancer of the prostate. In DeVita VT, Hellman S, Rosenberg SA eds, Cancer: Principles and Practice of Oncology. Chapt. XX, Philadelphia: Lippincott Williams & Wilkins, 2001: 1418
36. Zagars GK, Ayala AG, von Eschenbach AC et al. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long term follow-up study of 648 patients treated with radiation therapy. Int Radiat Oncol Biol Phys 1995; 31: 237-45
37. Kupelian P, Katcher J, Levin H et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer. therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997; 3: 78-87
38. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001; 57: 1121-6